Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 formulations, including semaglutide and tirzepatide-based treatments, for ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Good news for women of a certain age: Hormone ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Since the FDA considers tirzepatide “available,” stakeholders can no longer rely on the FDA’s shortage list exception ... The resolution of shortages for tirzepatide and other GLP-1 ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

Lexaria has completed other research with oral DehydraTECH-processed semaglutide, sold by Novo Nordisk®, which is the only GLP-1 drug available today both in an oral form (Rybelsus®) and as an ...